Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07532603) titled 'A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris' on April 3.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: Priovant Therapeutics, Inc.
Condition:
Lichen Planopilaris
Intervention:
Drug: Oral Brepocitinib
Recruitment Status: Recruiting
Phase: Phase 2/Phase 3
Date of First Enrollment: March 19, 2026
Target Sample Size: 342
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07...